New horizons for newborn brain protection: enhancing endogenous neuroprotection

K Jane Hassell, Mojgan Ezzati, Daniel Alonso-Alconada, Derek J Hausenloy, Nicola J Robertson

Research output: Contribution to journalReview articlepeer-review


Intrapartum-related events are the third leading cause of childhood mortality worldwide and result in one million neurodisabled survivors each year. Infants exposed to a perinatal insult typically present with neonatal encephalopathy (NE). The contribution of pure hypoxia-ischaemia (HI) to NE has been debated; over the last decade, the sensitising effect of inflammation in the aetiology of NE and neurodisability is recognised. Therapeutic hypothermia is standard care for NE in high-income countries; however, its benefit in encephalopathic babies with sepsis or in those born following chorioamnionitis is unclear. It is now recognised that the phases of brain injury extend into a tertiary phase, which lasts for weeks to years after the initial insult and opens up new possibilities for therapy.There has been a recent focus on understanding endogenous neuroprotection and how to boost it or to supplement its effectors therapeutically once damage to the brain has occurred as in NE. In this review, we focus on strategies that can augment the body's own endogenous neuroprotection. We discuss in particular remote ischaemic postconditioning whereby endogenous brain tolerance can be activated through hypoxia/reperfusion stimuli started immediately after the index hypoxic-ischaemic insult. Therapeutic hypothermia, melatonin, erythropoietin and cannabinoids are examples of ways we can supplement the endogenous response to HI to obtain its full neuroprotective potential. Achieving the correct balance of interventions at the correct time in relation to the nature and stage of injury will be a significant challenge in the next decade.

Original languageEnglish
Pages (from-to)F541-52
JournalArchives of Disease in Childhood. Fetal and Neonatal Edition
Issue number6
Publication statusPublished - Nov 2015


  • Asphyxia Neonatorum/drug therapy
  • Brain/physiopathology
  • Cannabinoids/adverse effects
  • Erythropoietin/adverse effects
  • Humans
  • Hypothermia, Induced/adverse effects
  • Hypoxia-Ischemia, Brain/physiopathology
  • Infant, Newborn
  • Melatonin/adverse effects
  • Neuroprotection/drug effects
  • Neuroprotective Agents/therapeutic use

Fingerprint Dive into the research topics of 'New horizons for newborn brain protection: enhancing endogenous neuroprotection'. Together they form a unique fingerprint.

Cite this